help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quintanilla-Martinez, L.
Right arrow Articles by Fend, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quintanilla-Martinez, L.
Right arrow Articles by Fend, F.
(American Journal of Pathology. 2003;162:1449-1461.)
© 2003 American Society for Investigative Pathology

Analysis of Signal Transducer and Activator of Transcription 3 (Stat 3) Pathway in Multiple Myeloma

Stat 3 Activation and Cyclin D1 Dysregulation Are Mutually Exclusive Events

Leticia Quintanilla-Martinez*, Marcus Kremer*{dagger}, Katja Specht*{dagger}, Julia Calzada-Wack*, Michaela Nathrath*, Robert Schaich*, Heinz Höfler{dagger} and Falko Fend{dagger}

From the Institutes of Pathology,*GSF-National Research Center for Health and Environment, Neuherberg; and the Technical University,{dagger}Munich, Germany

The signal transducer and activator of transcription molecules (Stats) play key roles in cytokine-induced signal transduction. Recently, it was proposed that constitutively activated Stat 3 (Stat 3 phosphorylated) contributes to the pathogenesis of multiple myeloma (MM) by preventing apoptosis and inducing proliferation. The study aim was to investigate Stat 3 activation in a series of multiple myeloma (MM) cases and its effect on downstream targets such as the anti-apoptotic proteins Bcl-xL, Mcl-1, and Bcl-2, and the cell-cycle protein cyclin D1. Forty-eight cases of MM were analyzed. Immunohistochemistry was performed on paraffin sections using antibodies against cyclin D1, Bcl-2, Bcl-xL, Mcl-1, p21, Stat 3, and Stat 3 phosphorylated (P). Their specificity was corroborated by Western blot analysis using eight human MM cell lines as control. The proliferation rate was assessed with the antibody MiB1. In addition, the mRNA levels of cyclin D1 and Stat 3 were determined by quantitative real-time reverse transcriptase-polymerase chain reaction of paraffin-embedded microdissected tissue. Three different groups determined by the expression of Stat 3P and cyclin D1 (protein and mRNA) were identified: group 1, Stat 3-activated (23 cases, 48%). All cases revealed nuclear expression of Stat 3P. No elevation of Stat 3 mRNA was identified in any of the cases. Three cases in this group showed intermediate to low cyclin D1 protein and mRNA expression. Group 2 included 15 (31%) cases with cyclin D1 staining and lack of Stat 3P. All cases showed intermediate to high levels of cyclin D1 mRNA expression. Group 3 included 10 (21%) cases with no expression of either cyclin D1 or Stat 3P. High levels of anti-apoptotic proteins Bcl-xL and Mcl-1 were identified in 89% and 100% of all cases, respectively. In contrast to Bcl-xL and Mcl-1, the expression of Bcl-2 showed an inverse correlation with proliferation rate (P: 0.0003). No significant differences were found between the three groups in terms of proliferation rate or expression of anti-apoptotic proteins. However, cyclin D1+ cases were always well differentiated and were more likely to show a lymphoplasmocytoid differentiation (chi-square = 9.55). Overall, constitutive activation of Stat 3 was found in almost half (48%) of the investigated MM cases. However, this does not seem to have a major impact on the expression of anti-apoptotic proteins and proliferation. We showed that cyclin D1 overexpression and Stat 3 activation are, mutually exclusive events in MM (P = 0.0066). The universal expression of Mcl-1, independent of activated Stat 3, suggests that its expression is constitutive and that it might play an important role in the pathogenesis of MM.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. Germain and D. A. Frank
Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy
Clin. Cancer Res., October 1, 2007; 13(19): 5665 - 5669.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S. Lassmann, I. Schuster, A. Walch, H. Gobel, U. Jutting, F. Makowiec, U. Hopt, and M. Werner
STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation
J. Clin. Pathol., February 1, 2007; 60(2): 173 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow, E. Samson, K. Bink, H. Hofler, F. Fend, J. Graw, and M. J. Atkinson
Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans
PNAS, October 17, 2006; 103(42): 15558 - 15563.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y. Ishii, A. Pirkmaier, J. V. Alvarez, D. A. Frank, I. Keselman, D. Logothetis, J. Mandeli, M. J. O'Connell, S. Waxman, and D. Germain
Cyclin d1 overexpression and response to bortezomib treatment in a breast cancer model.
J Natl Cancer Inst, September 6, 2006; 98(17): 1238 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Chen, I. R. Williams, B. H. Lee, N. Duclos, B. J. P. Huntly, D. J. Donoghue, and D. G. Gilliland
Constitutively activated FGFR3 mutants signal through PLC{gamma}-dependent and -independent pathways for hematopoietic transformation
Blood, July 1, 2005; 106(1): 328 - 337.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Fu, C. Wang, Z. Li, T. Sakamaki, and R. G. Pestell
Minireview: Cyclin D1: Normal and Abnormal Functions
Endocrinology, December 1, 2004; 145(12): 5439 - 5447.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Chatterjee, T. Stuhmer, P. Herrmann, K. Bommert, B. Dorken, and R. C. Bargou
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells
Blood, December 1, 2004; 104(12): 3712 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Specht, E. Haralambieva, K. Bink, M. Kremer, S. Mandl-Weber, I. Koch, R. Tomer, H. Hofler, E. Schuuring, P. M. Kluin, et al.
Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels
Blood, August 15, 2004; 104(4): 1120 - 1126.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C.-S. Chim, T.-K. Fung, W.-C. Cheung, R. Liang, and Y.-L. Kwong
SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway
Blood, June 15, 2004; 103(12): 4630 - 4635.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. W. Mandell
Phosphorylation State-Specific Antibodies: Applications in Investigative and Diagnostic Pathology
Am. J. Pathol., November 1, 2003; 163(5): 1687 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology, January 1, 2003; 2003(1): 248 - 278.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.